Abaxis Inc (ABAX) Receives $44.67 Average PT from Analysts

Abaxis Inc (NASDAQ:ABAX) has earned a consensus recommendation of “Hold” from the eight ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $44.67.

A number of research analysts recently issued reports on the company. Zacks Investment Research upgraded Abaxis from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 26th. BidaskClub raised Abaxis from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Aegis reaffirmed a “hold” rating on shares of Abaxis in a research report on Friday, December 1st. TheStreet raised Abaxis from a “c+” rating to a “b-” rating in a research report on Wednesday, November 29th. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $47.00 price objective (up from $46.00) on shares of Abaxis in a research report on Friday, October 27th.

Abaxis (NASDAQ ABAX) traded down $0.01 during trading hours on Monday, reaching $49.51. The company had a trading volume of 189,417 shares, compared to its average volume of 167,800. The stock has a market cap of $1,134.85, a P/E ratio of 41.26 and a beta of 0.86. Abaxis has a 12-month low of $43.66 and a 12-month high of $55.44.

Abaxis (NASDAQ:ABAX) last released its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. The firm had revenue of $58.90 million for the quarter, compared to the consensus estimate of $60.85 million. Abaxis had a return on equity of 10.18% and a net margin of 11.98%. The firm’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter last year, the business posted $0.34 EPS. research analysts expect that Abaxis will post 1.08 EPS for the current fiscal year.

Abaxis announced that its board has authorized a share repurchase program on Tuesday, October 24th that authorizes the company to buyback $21.00 million in shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 15th. Shareholders of record on Friday, December 1st were given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 1.29%. This is a boost from Abaxis’s previous quarterly dividend of $0.14. The ex-dividend date was Thursday, November 30th. Abaxis’s dividend payout ratio (DPR) is presently 53.33%.

A number of institutional investors have recently bought and sold shares of ABAX. Schwab Charles Investment Management Inc. lifted its position in Abaxis by 5.2% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 100,590 shares of the medical research company’s stock worth $5,334,000 after acquiring an additional 4,963 shares during the period. Arizona State Retirement System lifted its holdings in shares of Abaxis by 0.9% in the 2nd quarter. Arizona State Retirement System now owns 11,834 shares of the medical research company’s stock valued at $627,000 after buying an additional 100 shares during the period. Legal & General Group Plc lifted its holdings in shares of Abaxis by 9.9% in the 2nd quarter. Legal & General Group Plc now owns 44,532 shares of the medical research company’s stock valued at $2,360,000 after buying an additional 4,017 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in shares of Abaxis by 61.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,349 shares of the medical research company’s stock valued at $390,000 after buying an additional 2,795 shares during the period. Finally, Victory Capital Management Inc. lifted its holdings in shares of Abaxis by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 2,574 shares of the medical research company’s stock valued at $136,000 after buying an additional 386 shares during the period. 97.66% of the stock is owned by institutional investors.

WARNING: This article was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3126004/abaxis-inc-abax-receives-44-67-average-pt-from-analysts.html.

About Abaxis

Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.

Analyst Recommendations for Abaxis (NASDAQ:ABAX)

Receive News & Ratings for Abaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.